DMAC250117P2500
- 0.05
- 0.000.00%
DiaMedica Therapeutics Newsroom
Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Raises Target Price to $11
Individual Investors Are DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) Biggest Owners and Were Hit After Market Cap Dropped US$26m
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Diamedica Therapeutics (DMAC)
DiaMedica Therapeutics Management to Meet Virtually With Lake Street
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
Express News | DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of Dm199 for the Treatment of Preeclampsia
DiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth Plans
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
Lake Street Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC)
H.C. Wainwright Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
Express News | HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $7 Price Target
DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript Summary
DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript
DiaMedica Therapeutics Advances Trials and Financial Position
DiaMedica Therapeutics | 10-Q: Q3 2024 Earnings Report
DiaMedica Therapeutics | 8-K: DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
DiaMedica Therapeutics Reports Q3 EPS (15c), Consensus (15c)
Express News | DiaMedica Therapeutics Q3 2024 GAAP EPS $(0.15), Inline
Express News | DiaMedica Therapeutics Inc: Cash Runway Into Q3 2026